New hope for lymphoma patients: experimental drug VAY736 tested
NCT ID NCT04903197
First seen Jan 26, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This early-stage study tested an experimental drug called VAY736, alone or with other cancer drugs, in 18 adults with certain types of Non-Hodgkin lymphoma that had come back or not responded to standard treatments. The main goals were to check the drug's safety and how the body processes it. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA, DIFFUSE LARGE B CELL LYMPHOMA, FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Leipzig, 04103, Germany
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Yamagata, Yamagata, 990 9585, Japan
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
Conditions
Explore the condition pages connected to this study.